Bukwang Pharm (003000.KS)
Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, liver cirrhosis, and iron-deficiency anemia; over-the-counter drugs, such as fever and pain relief medication, gastrointestinal medication, cold medication, laxatives for constipation, collagen supplements, multivitamin supplements, mouthwash, topical gels, oral health supplements, and omega-3 supplements; and personal products comprising toothpastes, toothbrushes, and other oral care products; nutraceuticals; health functional foods; and quasi drugs. In addition, it offers products for various threptic areas, including endocrinology, gastroenterology, cardiology, oncology, central nervous system, iron supplements, neuropsychiatry, respiratory/allergy, dermatology, urology, and other treatment areas. Further, the company's development pipeline comprises Lurasidone for the treatment of schizophrenia and bipolar depression; JM-010, for treating dyskinesia in parkinson's disease; SOL-804, which is used for the treatment of metastatic castration resistant prostate cancer; AhR Inhibitor for solid tumors; PKR Inhibitor for neurodegenerative disorders; and PD Program for parkinson's disease. Bukwang Pharmaceutical Co., Ltd. was founded in 1960 and is headquartered in Seoul, South Korea.
Company Info
Highlights
₩296.05B
₩173.50B
₩79.58B
₩3,500.00 - ₩6,090.00
₩29,167.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Bukwang Pharm (003000.KS) returned -12.75% year-to-date (YTD) and -30.23% over the past 12 months. Over the past 10 years, 003000.KS returned -10.82% annually, underperforming the S&P 500 benchmark at 10.85%.
003000.KS
-12.75%
0.25%
-14.79%
-30.23%
-27.67%
-29.79%
-10.82%
^GSPC (Benchmark)
0.51%
3.96%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of 003000.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 2.07% | 2.24% | -18.68% | 2.44% | 0.38% | -12.75% | |||||||
| 2024 | 7.21% | 0.15% | 1.68% | -4.50% | -9.75% | -7.14% | 0.00% | -2.81% | -2.12% | -4.04% | -3.39% | -2.34% | -24.75% |
| 2023 | 3.77% | -8.48% | -3.61% | -0.12% | -3.75% | -6.88% | -6.97% | 1.20% | -8.00% | -8.53% | 6.69% | 0.66% | -30.29% |
| 2022 | -17.83% | 9.43% | 9.91% | -6.67% | -10.08% | -20.93% | 10.87% | -3.73% | -17.39% | 1.21% | 6.49% | 10.04% | -31.42% |
| 2021 | -20.28% | 24.33% | -15.26% | -8.26% | -2.31% | -4.26% | 2.47% | 4.58% | -30.88% | -13.00% | -8.81% | 9.23% | -53.74% |
| 2020 | -4.18% | -8.73% | 101.99% | 2.96% | 1.15% | 28.41% | 9.14% | 2.16% | -24.74% | -18.10% | 7.94% | 23.33% | 116.15% |
| 2019 | -6.25% | -2.15% | -16.04% | -3.93% | 0.54% | -5.15% | -12.00% | -9.74% | -0.36% | 5.42% | 0.00% | 4.60% | -38.42% |
| 2018 | 16.95% | -13.59% | 5.87% | 2.97% | 11.35% | -18.65% | -2.55% | 12.42% | 6.98% | -19.20% | 20.85% | 20.47% | 37.57% |
| 2017 | -14.77% | 4.44% | -9.15% | -2.34% | 9.83% | -6.77% | 1.17% | -1.16% | 4.45% | -0.67% | 14.22% | 3.51% | -0.80% |
| 2016 | 25.54% | -11.42% | 1.06% | -0.52% | 12.83% | 6.70% | -10.95% | -8.85% | 4.14% | -13.64% | -4.00% | 34.61% | 26.94% |
| 2015 | 15.73% | 15.29% | 11.16% | -6.44% | 18.42% | 15.21% | -21.51% | -6.81% | -8.92% | 12.03% | 1.39% | 12.58% | 61.29% |
| 2014 | -3.14% | -0.72% | 4.35% | 1.04% | -1.03% | 13.19% | 3.07% | 2.68% | 15.94% | -0.25% | -10.03% | 18.74% | 48.53% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 003000.KS is 9, meaning it’s performing worse than 91% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Bukwang Pharm (003000.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Bukwang Pharm provided a 0.00% dividend yield over the last twelve months, with an annual payout of ₩0.00 per share.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | ₩0.00 | ₩0.00 | ₩0.00 | ₩100.00 | ₩92.61 | ₩84.19 | ₩173.16 | ₩123.35 | ₩133.20 | ₩280.34 | ₩321.07 | ₩693.07 |
Dividend yield | 0.00% | 0.00% | 0.00% | 1.14% | 0.72% | 0.30% | 1.33% | 0.57% | 0.85% | 1.75% | 2.50% | 8.49% |
Monthly Dividends
The table displays the monthly dividend distributions for Bukwang Pharm. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | |||||||
| 2024 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 |
| 2023 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 |
| 2022 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩100.00 | ₩100.00 |
| 2021 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩92.61 | ₩92.61 |
| 2020 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩84.19 | ₩84.19 |
| 2019 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩173.16 | ₩173.16 |
| 2018 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩123.35 | ₩123.35 |
| 2017 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩133.20 | ₩133.20 |
| 2016 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩280.34 | ₩280.34 |
| 2015 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩321.07 | ₩321.07 |
| 2014 | ₩693.07 | ₩693.07 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Bukwang Pharm. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Bukwang Pharm was 90.31%, occurring on Apr 9, 2025. The portfolio has not yet recovered.
The current Bukwang Pharm drawdown is 89.16%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -90.31% | Jul 24, 2020 | 1154 | Apr 9, 2025 | — | — | — |
| -79.36% | Dec 22, 2004 | 962 | Oct 27, 2008 | 1634 | May 21, 2015 | 2596 |
| -74.68% | May 12, 1997 | 140 | Dec 3, 1997 | 54 | Mar 2, 1998 | 194 |
| -68.18% | Mar 4, 1998 | 72 | Jun 16, 1998 | 206 | Apr 23, 1999 | 278 |
| -53.15% | Mar 15, 2000 | 368 | Sep 17, 2001 | 635 | Apr 26, 2004 | 1003 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Bukwang Pharm over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Bukwang Pharm, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 1,847.1% positive surprise.
Valuation
The Valuation section provides an overview of how Bukwang Pharm is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 003000.KS compared to other companies in the Drug Manufacturers - Specialty & Generic industry. 003000.KS currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 003000.KS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 003000.KS has a P/S ratio of 1.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 003000.KS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 003000.KS has a P/B value of 1.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |